DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
15 juin 2023 09h00 HE
|
DepYmed, Inc.
FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
31 mai 2023 09h30 HE
|
DepYmed, Inc.
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
16 nov. 2022 09h35 HE
|
DepYmed, Inc.
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
03 mai 2022 09h42 HE
|
DepYmed, Inc.
FARMINGDALE, N.Y., May 03, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...